Grade 3–4 AEs | Nanoliposomal irinotecan-based therapy (%) | 5-FU and OXA-based therapy weighted average (%) [range] |
---|---|---|
Diarrhea | 13 | 4.2 [0, 14.2] |
Vomiting | 11 | 4.1 [0, 13.5] |
Fatigue | 14 | 11.7 [0, 14.8] |
Neutropenia | 27 | 21.5 [7.4, 32.7] |
Anemia | 9 | 4.5 [0, 14] |
Hypokalemia | 3 | NR |
Neurotoxicity | NR | 5.3 [0, 12] |
Thrombocytopenia | NR | 4.9 [0, 11.1] |